Leap Therapeutics (NASDAQ:LPTX) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Leap Therapeutics (NASDAQ:LPTX) released its quarterly earnings data on Monday. The company reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.02, Zacks reports.

Leap Therapeutics Trading Down 0.5 %

NASDAQ LPTX opened at $0.39 on Wednesday. The firm has a market capitalization of $14.87 million, a P/E ratio of -0.20 and a beta of 0.35. The firm’s fifty day moving average price is $0.89 and its two-hundred day moving average price is $2.23. Leap Therapeutics has a 1 year low of $0.39 and a 1 year high of $4.79.

Wall Street Analyst Weigh In

LPTX has been the subject of a number of research analyst reports. Robert W. Baird lowered shares of Leap Therapeutics from an “outperform” rating to a “neutral” rating and reduced their target price for the stock from $9.00 to $1.25 in a research note on Wednesday, January 29th. Baird R W lowered shares of Leap Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, January 29th. Finally, HC Wainwright downgraded shares of Leap Therapeutics from a “buy” rating to a “neutral” rating in a research note on Wednesday, January 29th.

Leap Therapeutics Company Profile

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.